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Methods: Two randomized, placebo-controlled trials investigated SB742457 15 and 35 mg daily in
subjects with mild-to-moderate AD (Mini-Mental Health State Examination [MMSE] 10–26). Study
1 (n 5 576) investigated SB742457 and donepezil (5–10 mg daily) as monotherapy for 6 months.
Study 2 (n5 684) investigated SB742457 in subjects who were maintained on donepezil. Coprimary
endpoints at 24 weeks assessed cognition (AD Assessment Scale-Cognitive Subscale [ADAS-Cog])
and global outcome (Study 1: Clinician Interview-Based Impression of Change Plus Caregiver Input
[CIBIC1]; Study 2: Clinical Dementia Rating-Sum of Boxes [CDR-SB]). Safety was assessed
throughout.
Results: Both studies failed to achieve formal statistical significance for their primary objectives.
Study 1: SB742457 monotherapy was not statistically significantly different from placebo on any
endpoint. Donepezil improved CIBIC1 but not ADAS-Cog. Study 2: SB742457 35 mg showed sta-
tistically significant differences relative to placebo for ADAS-cog (weeks 12, 24, and 48, but not week
36), ADCS-ADL (weeks 12–36, but not week 48), and CDR-SB (week 12 only).
Conclusion: Neither study met the overall criteria for success, but as an adjunct to donepezil,
SB742457 was associated with sustained improvements for up to 48 weeks in cognition and ADL,
compared with donepezil alone.
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Serotonin (5-hydroxytryptamine [5-HT]) plays a role in
cognition and behavior, therefore, pharmacological agents
that impact 5-HT pathways are of interest in Alzheimer’s
disease (AD). In particular, 5-HT6 receptors are found
almost exclusively within the central nervous system in re-
gions associated with cognition and behavior, including
the striatum, nucleus accumbens, and to a lesser extent the
hippocampus and cerebral cortex [1].
SB742457 is a potent and selective 5-HT6 receptor antag-
onist shown to reverse scopolamine-induced deficits in a ro-
dent test of novel object recognition, and to enhance
performance of a water maze task by aged rats [1]. Other
5-HT6 receptor antagonists have also shown activity in these
tests and in similar models [2–4]. Results from two previous
Phase II studies of SB742457 as monotherapy, suggested
some improvements in cognition and global function in
patients with mild-to-moderate AD [5,6]. Post hoc
analyses suggested that effects on cognition, measured
using the AD Assessment Scale-cognitive subscale
(ADAS-Cog), may be more evident in patients with moder-
ate AD than in those with mild AD.
5-HT6 antagonists have modulatory effects on
cholinergic, glutamatergic, and monoaminergic systems
[7–11]. Although the relative contributions of these
neurotransmitter effects on cognition is unknown, this
action is clearly distinct from that of acetylcholinesterase
inhibitors (AChEIs) [3,4], which are approved for the
symptomatic management of mild-to-moderate AD [12].
An adjunctive therapy that acts via a different neurotrans-
mitter system to AChEIs could offer enhanced cognitive
benefits. There are currently no treatments approved for
adjunct therapy to AChEIs in mild-to-moderate AD, but pre-
liminary data suggest that there are additive effects with
AChEIs and 5-HT6 antagonists in preclinical cognition
models [13].
Here, the results of two Phase II studies in patients with
probable mild-to-moderate AD are presented:
 Study 1 was performed to investigate the efficacy and
safety of SB742457 15 and 35 mg when used as mono-
therapy for 24 weeks, comparedwith placebo. Donepe-
zil was also included as an active control.
 Study 2 examined the same doses of SB742457 as an
adjunct treatment to donepezil therapy over 48 weeks,
compared with placebo.2. Methods
2.1. Study details
The study design and methodology are summarized later.
Additional details are provided in the Technical
Appendix. Study 1 (GlaxoSmithKline study: AZ3110865;
ClinicalTrials.gov identifier: NCT00708552) and Study 2
(GlaxoSmithKline study: AZ3110866; ClinicalTrials.govidentifier: NCT00710684) were multicenter, double-blind,
randomized, placebo-controlled, parallel-group trials.
Study 1 was conducted from July 2008 to March 2010 in
68 centers across 11 countries (Bulgaria, Chile, Czech Re-
public, Estonia, Germany, Greece, Korea, Mexico, Poland,
Russia, and South Africa). Study 2 was conducted from
July 2008 to November 2010 in 97 centers across nine coun-
tries (Argentina, Australia, Canada, Chile, Czech Republic,
Germany, Italy, Spain, and USA).
The studies were conducted in accordance with Good
Clinical Practice guidelines and the Declaration of Helsinki.
The protocol was reviewed and approved by properly consti-
tuted ethics committees (national, regional, or investiga-
tional) or institutional review boards at each participating
institution.
2.2. Research participants
Eligible participants were aged 50 to 85 years inclusive;
met the criteria for probable AD in accordance with Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition criteria [14] and National Institute of Neurological
and Communicative Diseases and Stroke/Alzheimer’s Dis-
ease and Related Disorders Association criteria [15]; had a
stable Mini-Mental Status Examination (MMSE) [16] score
of 10 to 26 before randomization (with 3-point variation
from screening to the end of the run-in period); had a Ha-
chinski Ischemia score [17] of 4 at screening; and had a
regular caregiver to assess cognitive function, activities of
daily living (ADL), and behavior. In Study 2, participants
were also required to have 6 months’ history of donepezil
therapy, with 2 months at a stable dose and no intent to
change during the study.
Exclusion criteria included: significant psychiatric
illness; history/evidence of another cause of dementia; his-
tory of seizures; known history of drug-related photosensi-
tivity; abnormal findings precluding participation; or use of
AChEIs (with the exception of donepezil in Study 2),
memantine, selegiline, monoamine oxidase inhibitors, con-
ventional antipsychotics, an investigational drug, or treat-
ment with potential for interaction with SB742457.
Antidepressants (other than monoamine oxidase inhibi-
tors), thyroid hormones, atypical antipsychotics, benzodi-
azepines, and other sedatives/hypnotics were permitted
conditionally if prescribed at a stable dose for
2 months before entry.
2.3. Study procedures
In both studies, research participants entered a 2-week
screening period and a 4-week single-blind placebo run-in
period.
 In Study 1, participants then entered a 24-week treat-
ment phase, receiving SB742457 (15 or 35 mg), done-
pezil (5–10 mg [an active control to assess assay
sensitivity]), or placebo.
G. Maher-Edwards et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 23-36 25 In Study 2, participants taking stable donepezil therapy
initially entered a 24-week treatment phase, receiving
SB742457 (15 or 35 mg) or placebo. At the end of
the 24-week treatment period, participants were
offered the opportunity to continue the treatment phase
from 24 to 48 weeks, on their existing medication.
In both studies a follow-up visit was performed 2 weeks
after the last treatment dose.2.4. Randomization and masking
In both studies, SB742457 35 and 15 mg and matching
placebo were provided by GlaxoSmithKline as tablets, and
were indistinguishable in appearance, smell, and taste. For
Study 1, donepezil was externally sourced by GlaxoSmithK-
line and encapsulated to provide 5 mg, 10 mg, and matching
placebo capsules.
In Study 1, research participants were randomized in a
1:1:1:1 ratio, in random permuted blocks of 8, to
SB742457 (15 or 35 mg), donepezil 5–10 mg, or placebo.
Supplies were double-dummy; subjects received one tablet
of SB742457 or matching placebo and also one capsule of
donepezil or matching placebo each evening.
In Study 2, randomization was in blocks of 6, in a 1:1:1
ratio to SB742457 (15 or 35 mg) or placebo, in addition to
their ongoing background donepezil therapy. The randomi-
zation schedule was generated by GlaxoSmithKline and im-
plemented using an interactive voice-response system.
Randomization in both studies was stratified according to
baseline MMSE score (MMSE 10–15 30% subjects;
MMSE 16–20 60% subjects; and MMSE 21–26 30%
subjects) to ensure a balance of subjects across the mild-
to-moderate range.2.5. Outcomes and assessments
Efficacy assessments were conducted at screening and
then at the end of the run-in period to provide a baseline
assessment and then at weeks 12 and 24 in both studies,
with further assessments at weeks 36 and 48 in Study 2.
Change from baseline in ADAS-Cog at week 24 was a copri-
mary endpoint in both studies. The Clinician Interview-
Based Impression of Change plus Caregiver Input (CIBIC1)
score [18] at week 24 was the coprimary global endpoint in
Study 1, and the Clinical Dementia Rating-Sum of Boxes
(CDR-SB) [19] at week 24 was the coprimary global
endpoint in Study 2. In a post hoc analysis the primary end-
points were also assessed across two subgroups according to
the baseline MMSE score (mild, MMSE 20–26; moderate,
MMSE 10–19).
Secondary endpoints for both studies included the AD
Co-operative Study-Activities of Daily Living Scale
(ADCS-ADL) [20], the Repeatable Battery for Assessment
of Neuropsychological Status (RBANS) [21], and the
MMSE [16]. The Cornell Scale for Depression in Dementia(CSDD) [22] was an additional secondary endpoint in
Study 1.
Standard safety assessments were performed at all visits,
including physical examinations, pregnancy tests (if appli-
cable), and assessments of adverse events (AEs), serious
AEs (SAEs), vital signs, and electrocardiograms (ECGs).
Routine laboratory assessments of clinical chemistry, hema-
tology, and urinalysis parameters were also performed. As
Study 2 was the first to coadminister SB742457 and donepe-
zil, safety and pharmacokinetic data were reviewed by an In-
dependent Data Monitoring Committee (IDMC) to evaluate
potential interactions.
Pharmacokinetic parameters assessed in Study 2
included steady-state concentrations and area under the
curve. Potential pharmacodynamic interactions between
SB742457 and donepezil were assessed in a subgroup of
subjects based on red blood cell acetylcholinesterase
activity.2.6. Statistical analysis
The studies were powered to detect a standardized ef-
fect size (treatment difference/standard deviation [SD])
of 0.42 for Study 1 and 0.33 for Study 2, with 90% power
and a 0.05 significance level, under an assumed SD. This
relates to a difference of 2.5 and 2 points in change from
baseline in ADAS-Cog for Study 1 and 2, respectively
(under an assumed SD of 6), and a difference of 0.47
for CIBIC1 (under an assumed SD of 1.12) for Study 1
and a difference in change from baseline in CDR-SB of
0.6 for Study 2 (under an assumed SD of 1.8). This
required 122 and 190 subjects per treatment group for
Study 1 and 2, respectively. Assuming a postrandomiza-
tion drop-out rate of 15%, 576 subjects were planned
for randomization in Study 1 and 672 subjects were
planned for Study 2.
The two coprimary endpoints in each study needed to
achieve a significance level of 0.05 at the same dose, to
maintain an overall 5% significance level. A hierarchy
was followed to account for the multiplicity of doses,
with SB742457 35 mg being the primary comparison.
Formal inferential testing was only performed for
SB742457 15 mg if the first comparison, on both copri-
mary endpoints was significant. Primary inference was
conducted using a mixed model for repeated measures
analysis using restricted maximum likelihood estimation
[23]. Other P values presented have been interpreted in
light of the testing hierarchy; the analyses of all secondary
endpoints were considered exploratory and were not inter-
preted inferentially.
The intent-to-treat (ITT) population used in efficacy an-
alyses comprised all randomized subjects who took 1
dose of study medication and who had 1 postbaseline ef-
ficacy assessment. The safety population consisted of all
randomized subjects who took 1 dose of study
medication.
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3.1. Subject disposition and demographics
The screening, randomization, and completion rate of
subjects in each study are outlined in Fig. 1. In Study 1,
967 subjects were screened, 576 were randomized, and
493 (86%) completed the 24-week trial. In Study 2, 1132
subjects were screened and 684 were randomized. Of the
599 (88%) subjects who completed the 24-week treatment
period, 537 consented to continue treatment to week 48.
There were 67 discontinuations during the second 6 months
of the trial and 470 (69%) subjects completed the 48-week
study. The IDMC found no reason to stop or alter the conduct
or design of the study.
The most common reasons for withdrawal across the
studies were AEs and withdrawn consent (Fig. 1).
Demographic and baseline characteristics were similar
across all treatment groups (Table 1). Most subjects in
each study (.90%) were white and approximately 60%
were female. The mean baseline MMSE score of 18 in
each study reflected the stratified study designs and was
consistent with the subject populations having mild-to-
moderate AD.3.2. Efficacy assessments3.2.1. Study 1 (monotherapy)
At week 24, none of the treatment groups (SB742457 35
or 15 mg, or donepezil) produced a statistically significant
difference on ADAS-Cog versus placebo (Table 2). For
CIBIC1, there was no significant difference between pla-
cebo and either dose of SB742457, but donepezil was asso-
ciated with a significant improvement versus placebo
(P 5 .049). The observed SD values were found to compare
well with the protocol assumptions (see Supplementary
Materials for further details). No statistically significant
baseline MMSE treatment interactions were observed
(Table 3).
There were also no statistically significant differences be-
tween SB742457 and placebo on the secondary endpoints in
the study, namely ADCS-ADL, RBANS, MMSE, or CSDD
(Table 2; Fig. 2). Donepezil was associated with a significant
improvement in MMSE versus placebo (P 5 .044) but not
for other endpoints.
3.2.2. Study 2 (adjunct to donepezil)
The study demonstrated a statistically significant
improvement in ADAS-Cog for SB742457 35 mg versus
placebo at week 24 (P5 .012; Table 2). The effects at weeks
36 and 48 were consistent with the primary analyses at week
24 (Fig. 2), with a difference of 1.6 points (P5 .024) versus
placebo at week 48. For CDR-SB, there was no statistically
significant difference between SB742457 35mg and placebo
at week 24 or week 48 (Table 2). Overall, the observed SD
values compared well with the protocol assumptions (seeSupplementary Materials for further details). However, the
study failed to meet the requirement for statistically signifi-
cant efficacy on both coprimary endpoints for SB742457
35 mg, and, in accordance with the prespecified testing hier-
archy, inferential testing for SB742457 15 mg was not per-
formed.
An increase in ADCS-ADLwas observedwith SB742457
35 mg at week 12, and at week 24 the improvement was sta-
tistically significant versus placebo (P5 .033; Table 2). This
improvement was maintained through to week 48, although
at week 48 the difference was not statistically significant
(P 5 .088) (Fig. 2). Significant differences versus placebo
were not observed for RBANS or MMSE (Table 2; Fig. 2).
No statistically significant baseline MMSE treatment inter-
actions were observed for the full ITT population, at either
week 24 or week 48 (Table 3).3.3. Safety and tolerability
On-treatment AEs were reported by 33% of subjects in
Study 1. The cumulative incidence of on-treatment AEs in
Study 2 was 60% at week 48. Within each study, the propor-
tion of subjects reporting any on-treatment AE was similar
across the treatment groups (Tables 4 and 5). Most AEs in
both studies were of mild-to-moderate intensity. Headache,
nasopharyngitis, and diarrhea were among the top five
most common AEs for both studies (Tables 4 and 5).
The incidence of drug-related AEs, AEs leading to with-
drawal, and SAEs was low and similar across the treatment
groups in each study. The incidence of drug-related AEs was
6%–15% in Study 1 and 7%–13% in Study 2, whereas the
incidence of AEs leading to withdrawal was 2%–6% in
Study 1 and 7%–9% in Study 2. SAEs occurred at an inci-
dence of 2%–7% across treatment groups in Study 1, and
8%–12% in Study 2 (Supplementary Table 1).
Three deaths were reported during Study 1 (SB742457
35 mg, donepezil, and placebo, all n 5 1 [,1%]), and 10
deaths were reported in Study 2 (SB742457 35 mg, n 5 4
[2%]; SB742457 15 mg, n 5 5 [2%]; placebo, n 5 1
[,1%]; see Supplementary Table 2). Two of the 10 deaths
in Study 2 were reported in the week 24 analyses, and eight
were reported between weeks 24 and 48; the only causes of
death in more than one subject were pneumonia and cerebro-
vascular accident. None of the deaths in either study were
considered by the study investigator to be drug related.
Mean changes in hematology, clinical chemistry, urinaly-
sis, vital signs, and ECG parameters were generally small,
not clinically relevant, and were comparable across treat-
ment groups in both studies.3.4. Pharmacokinetics and pharmacodynamics
Plasma exposures of SB742457 (minimum steady state
concentration; area under the curve over the dosing interval
at steady state) and donepezil (average concentration
at steady state) were similar between the studies
Fig. 1. Flow of subjects through Study 1 (A) and Study 2 (B). ITT, intent-to-treat.
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terase activities were similar before and after randomized
adjunctive therapy for each treatment group in Study 2.
Week 3 to baseline ratios (90% confidence intervals) were
1.01 (0.98, 1.05), 1.00 (0.97, 1.04), and 1.00 (0.97, 1.03)
for placebo, SB742457 15 mg, and SB742457 35 mg,
respectively.4. Discussion
Two randomized, double-blind, placebo-controlled,
Phase II trials of SB742457, as monotherapy and as
add-on to donepezil, were conducted in subjects with
mild-to-moderate AD. As monotherapy, SB742457 did
not show a benefit on coprimary endpoints of cognition
and global function. However, SB742457 35 mg added
Table 1
Summary of baseline demographic, AD characteristics, and efficacy assessment scores
Population
Study 1 Study 2
Placebo
(N 5 135)
SB742457
15 mg
(N 5 142)
SB742457
35 mg
(N 5 130)
Donepezil
5–10 mg
(N 5 147)
Placebo 1 donepezil
(N 5 223)
SB742457
15 mg 1 donepezil
(N 5 218)
SB742457
35 mg 1 donepezil
(N 5 236)
Gender, % male:female 36:64 32:68 42:58 35:65 42:58 46:54 37:63
Age, yrs 73.3 (6.80) 72.4 (8.12) 72.5 (7.38) 71.1 (7.49) 73.1 (7.49) 74.2 (6.82) 73.8 (6.92)
BMI, kg/m2 26.2 (4.04) 26.3 (4.44) 26.3 (3.97) 26.1 (4.10) 26.2 (4.44) 26.5 (4.57) 26.2 (4.33)
Education, yrs 11.5 (3.66) 11.0 (3.73) 10.7 (3.43) 11.3 (3.56) 10.3 (4.0) 10.0 (3.8) 10.4 (4.0)
Family history of AD:
yes, n (%)
30 (22) 28 (20) 24 (18) 29 (20) 72 (32) 59 (27) 63 (27)
Median time since first
diagnosis, yrs
1.1 1.1 0.7 0.9 2.1 1.7 1.9
MMSE 18.2 (3.88) 18.7 (3.68) 18.6 (3.64) 18.7 (3.75) 18.4 (3.94) 18.8 (3.71) 18.7 (3.87)
Median MMSE (range) 18 (10–26) 19 (10–26) 19 (11–26) 19 (10–26) 19 (10–26) 19 (10–26) 19 (10–26)
ADAS-Cog 29.1 (12.43) 27.9 (10.72) 28.2 (10.80) 26.2 (11.41) 27.1 (11.29) 26.5 (10.11) 27.1 (10.76)
CDR-SB – – – – 7.11 (3.514) 6.94 (3.382) 7.07 (3.433)
RBANS total 94.3 (38.67) 98.0 (36.98) 97.2 (38.79) 100 (41.28) 92.1 (37.51) 98.0 (36.00) 96.3 (36.33)
ADCS-ADL total 51.5 (17.78) 52.4 (16.31) 52.2 (15.07) 53.1 (15.88) 52.1 (16.36) 51.4 (16.37) 51.5 (16.30)
Abbreviations: AD, Alzheimer’s disease; BMI, body mass index; MMSE, Mini-Mental Status Examination; ADAS-Cog, Alzheimer’s Disease Assessment
Scale-Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Co-operative Study-Activities of Daily Living Scale; CDR-SB, Clinical Dementia Rating-Sum of
Boxes; RBANS, Repeatable Battery for Assessment of Neuropsychological Status; SD, standard deviation.
NOTE. Data presented as mean (SD) unless otherwise stated.
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ADAS-Cog versus placebo in Study 2, and the magnitude
of the effect was maintained throughout the 48-week
treatment period. Significant improvements in function
were also observed over the same time course, as
measured by the ADCS-ADL, with SB742457 35 mg.
However, the lack of effect on the other coprimary
endpoint (CDR-SB) meant that the study failed to meet
the overall criteria for success. Although there is no
consensus regarding the definition of a clinically relevant
benefit for an adjunctive therapy in patients with mild-to-
moderate AD, the sustained magnitude of effect over
48 weeks in both cognitive and functional parameters sug-
gests an effect of potential clinical value. The results for
the coprimary endpoints were found to be unaffected by
baseline MMSE scores.
Preliminary preclinical data using cognitive models
and microdialysis suggest that there is a positive interac-
tion between AChEIs and 5-HT6 antagonists, which may
be related to additive effects on the cholinergic system
(GlaxoSmithKline, unpublished data). 5-HT6 antagonists
have also been shown to increase the release of other neu-
rotransmitters such as glutamate and monoamines [7–10].
These mechanisms may explain the effects over and above
those offered by cholinesterase inhibition, but further
studies are needed to characterize any potential additive
or synergistic interactions between 5-HT6 antagonists
and AChEIs. As such, it was decided to conduct two
studies in parallel to investigate both the monotherapy ef-
fects and the add-on effects. In addition to Study 1 re-
ported here, two other studies have assessed SB742457
as monotherapy in AD [5,6]. Overall, the three studieshave produced inconsistent results, which suggest that
SB742457 is unlikely to be useful as monotherapy.
These observations are consistent with other recent
studies of monotherapy in AD, which have also proved
unsuccessful [24,25]. As donepezil did not demonstrate
the expected level of efficacy, and no effect could be
detected on the ADAS-Cog, there may also have been
problems with assay sensitivity in Study 1. It is therefore
possible that short-term monotherapy studies in drug-
na€ıve patients are no longer suitable for the study of
new treatments, especially given the wider availability
of AChEIs and memantine.
Other factors that can influence aspects of data vari-
ability in large clinical trials include the inconsistent
application of entry criteria across study sites, differences
in clinical practice and clinical trial experience across
sites, and the language and culture of participating coun-
tries. Furthermore, the number and order of assessments
and their impact on patient fatigue, the range and sensi-
tivity of scales, and the reliability and consistency of
caregiver-reported outcomes have been identified as
important areas for consideration in the design of random-
ized clinical trials in AD [26–28]. The two studies
reported here were designed to mirror each other as far
as possible in study design, and subject demographic
profiles were generally similar across the studies. As
such, a clear factor of study design or population does
not account for the additive effects observed in Study 2,
and it is difficult to establish whether any combination
of factors could provide an explanation. Although a
number of factors could potentially have introduced
unwanted variability, there was sufficient power to
Table 2
Summary of repeated measures analysis of change from baseline in primary and secondary endpoints in Study 1 and Study 2
Assessment
Study 1 Study 2
Week 12 Week 24 Week 24y Week 48z
n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) n
Adjusted
mean (SE)
Difference vs
placebo (95% CI)
P-
value* n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) P-value* n
Adjusted
mean (SE)
Difference vs placebo
(95% CI)
Secondary endpoints Coprimary endpoints Coprimary endpoints Secondary endpoints
ADAS-Cog
Placebox 124 20.1 (0.45) 116 20.3 (0.56) 193 1.2 (0.45) 145 3.4 (0.52)
SB742457 15 mgx 133 0.0 (0.46) 0.1 (21.1, 1.4) 124 0.8 (0.58)
1.1 (20.4, 2.7)
.159 184 0.5 (0.44) 20.7 (21.9, 0.5) .279 142 3.4 (0.60) 20.1 (21.6, 1.5)
SB742457 35 mgx 126 20.2 (0.45) 20.1 (21.4, 1.1) 115 0.4 (0.62)
0.7 (20.9, 2.3)
.410 200 20.4 (0.41) 21.5 (22.7, 20.3) .012 170 1.8 (0.50) 21.6 (23.1, 20.2)
Donepezil 5–10 mg 137 20.6 (0.40) 20.5 (21.6, 0.7) 123 20.5 (0.45)
20.2 (21.6, 1.2)
.821 – – – – – – –
CIBIC1 (Study 1)/CDR-SB (Study 2)
Placebox 126 3.9 (0.08) 118 4.0 (0.11) 191 0.9 (0.13) 146 1.6 (0.16)
SB742457 15 mgx 133 4.0 (0.08) 0.1 (201, 0.3) 125 4.2 (0.10)
0.2 (20.1, 0.5)
.254 184 0.8 (0.13) 20.1 (20.4, 0.3) .711 142 1.9 (0.20) 0.3 (20.2, 0.8)
SB742457 35 mgx 126 3.9 (0.09) 0.0 (20.2, 0.2) 117 3.9 (0.10)
20.1 (20.4, 0.2)
.394 200 0.7 (0.11) 20.1 (20.5, 0.2) .462 170 1.5 (0.16) 20.1 (20.5, 0.4)
Donepezil 5–10 mg 139 3.7 (0.08) 20.2 (20.4, 0.0) 127 3.7 (0.10)
20.3 (20.6, 0.0)
.049 – – – – – – –
Secondary endpoints Secondary endpoints
ADCS-ADL total
Placebox 126 20.4 (0.59) 118 21.0 (0.71) 191 23.2 (0.65) 147 25.5 (0.85)
SB742457 15 mgx 133 21.1 (0.65) 20.7 (22.4, 1.0) 123 21.4 (0.68)
20.3 (22.3, 1.6)
184 21.9 (0.62) 1.3 (20.4, 3.1) 144 25.0 (0.87) 0.5 (21.9, 2.9)
SB742457 35 mgx 124 20.1 (0.64) 0.3 (21.4, 2.0) 114 21.1 (0.81)
20.1 (22.2, 2.0)
202 21.3 (0.61) 1.9 (0.2, 3.6) 171 23.5 (0.76) 1.9 (20.3, 4.2)
Donepezil 5–10 mg 139 0.2 (0.62) 0.6 (21.1, 2.2) 128 21.2 (0.82)
20.1 (22.3, 2.0)
– – – – –
RBANS
Placebox 125 26.7 (1.16) 116 22.3 (1.44) 190 23.6 (1.18) 143 27.3 (1.36)
SB742457 15 mgx 134 28.7 (1.24) 21.9 (25.2, 1.4) 125 24.0 (1.42)
21.6 (25.6, 2.3)
176 25.9 (1.29) 22.4 (25.8, 1.1) 136 29.4 (1.45) 22.1 (26.0, 1.8)
SB742457 35 mgx 125 25.9 (1.11) 0.9 (22.2, 4.0) 115 24.4 (1.49)
22.1 (26.1, 1.9)
193 24.0 (1.09) 20.5 (23.6, 2.7) 164 24.7 (1.25) 2.6 (21.0, 6.2)
Donepezil 5–10 mg 138 23.4 (1.06) 3.4 (0.3, 6.4) 127 20.3 (1.21)
2.0 (21.7, 5.7)
– – – – – –
(Continued )
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Table 2
Summary of repeated measures analysis of change from baseline in primary and secondary endpoints in Study 1 and Study 2 (Continued )
Assessment
Study 1 Study 2
Week 12 Week 24 Week 24y Week 48z
n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) n
Adjusted
mean (SE)
Difference vs
placebo (95% CI)
P-
value* n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) P-value* n
Adjusted
mean (SE)
Difference vs placebo
(95% CI)
Secondary endpoints Coprimary endpoints Coprimary endpoints Secondary endpoints
MMSE
Placebox Not assessed 118 20.3 (0.29) 195 20.4 (0.21) 149 21.1 (0.28)
SB742457 15 mgx 124 20.3 (0.28)
0.0 (20.8, 0.8)
187 20.3 (0.23) 0.0 (20.6, 0.6) 145 21.3 (0.33) 20.1 (21.0, 0.7)
SB742457 35 mgx 117 20.1 (0.29)
0.3 (20.5, 1.1)
202 20.0 (0.21) 0.3 (20.2, 0.9) 172 20.7 (0.27) 0.4 (20.3, 1.2)
Donepezil 5–10 mg 128 0.5 (0.27)
0.8 (0.0, 1.6)
– – – – – –
CSDD
Placebox Not assessed 118 0.0 (0.26) Not assessed
SB742457 15 mgx 125 20.1 (0.25)
20.2 (20.9, 0.5)
SB742457 35 mgx 117 0.3 (0.26)
0.2 (20.5, 0.9)
Donepezil 5–10 mg 128 0.3 (0.25)
0.3 (20.4, 1.0)
Abbreviations: SE, standard error; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; CIBIC1, Clinician Interview-Based Impression of Change Plus Caregiver Input; ADCS-ADL,
Alzheimer’s Disease Co-operative Study-Activities of Daily Living Scale; CI, confidence interval; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CI, confidence interval; CSDD, Cornell Scale for Depression
in Dementia; MMSE, Mini-Mental Status Examination; RBANS, Repeatable Battery for Assessment of Neuropsychological Status.
NOTE. ADAS-Cog and CDR-SB: a negative difference represents benefit over placebo.
*Only P values for the primary endpoints are shown.
yFrom the week 24 analysis data set (includes all data from the primary analysis, up to and including the week 24 visit).
zFrom the week 48 analysis data set (includes all data from the analysis of the complete and final data set, up to and including the week 48 visit).
xIn Study 2, SB742457 and placebo were administered as an adjunct to stable donepezil therapy.
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Table 3
Summary of repeated measures analysis of change from baseline in ADAS-Cog total score, CIBIC1, and CDR-SB in mild and moderate groups
Assessment
Study 1 Study 2
Week 24 Week 24* Week 48y
n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) n
Adjusted
mean (SE)
Difference vs
placebo (95% CI) n
Adjusted
mean (SE)
Difference vs
placebo (95% CI)
cDAS-Cog cDAS-Cog
Mild (MMSE 20–26)
Placeboz 50 21.2 (0.80) 89 1.2 (0.66) 66 1.9 (0.70)
SB742457 15 mgz 55 20.2 (0.77) 1.0 (21.2, 3.1) 78 20.1 (0.56) 21.3 (23.0, 0.4) 64 1.9 (0.85) 0.0 (22.1, 2.2)
SB742457 35 mgz 50 21.0 (0.97) 0.2 (22.3, 2.6) 102 21.2 (0.45) 22.4 (24.0, 20.8)* 89 0.5 (0.60) 21.3 (23.1, 0.5)
Donepezil 5–10 mg 56 21.4 (0.66) 20.3 (22.3, 1.7) – – – – – –
Moderate (MMSE 10–19)
Placeboz 66 0.3 (0.78) 104 1.2 (0.61) 79 4.8 (0.77)
SB742457 15 mgz 69 1.7 (0.86) 1.4 (20.9, 3.7) 106 1.2 (0.63) 0.1 (21.7, 1.8) 78 4.9 (0.86) 0.1 (22.1, 2.4)
SB742457 35 mgz 65 1.7 (0.78) 1.4 (20.8, 3.5) 98 0.5 (0.69) 20.7 (22.5, 1.1) 81 3.0 (0.80) 21.8 (24.0, 0.4)
Donepezil 5–10 mg 67 0.3 (0.64) 0.0 (22.0, 2.0) – – – – – –
CIBIC1 CDR-SB
Mild (MMSE 20–26)
Placeboz 50 3.6 (0.14) 88 0.4 (0.16) 63 0.9 (0.19)
SB742457 15 mgz 56 3.9 (0.13) 0.3 (20.1, 0.6) 76 0.5 (0.17) 0.1 (20.3, 0.6) 64 1.4 (0.30) 0.5 (20.2, 1.2)
SB742457 35 mgz 50 3.6 (0.16) 20.1 (20.5, 0.3) 100 0.3 (0.13) 0.0 (20.4, 0.3) 88 1.0 (0.21) 0.1 (20.5, 0.6)
Donepezil 5–10 mg 56 3.4 (0.16) 20.2 (20.7, 0.2) – – – – – –
Moderate (MMSE 10–19)
Placeboz 68 4.3 (0.16) 103 1.2 (0.21) 83 2.1 (0.24)
SB742457 15 mgz 69 4.4 (0.14) 0.1 (20.3, 0.6) 108 1.0 (0.19) 20.3 (20.8, 0.3) 78 2.3 (0.27) 0.2 (20.5, 0.9)
SB742457 35 mgz 67 4.2 (0.13) 20.1 (20.5, 0.3) 100 1.0 (0.18) 20.2 (20.7, 0.3) 82 1.9 (0.24) 20.2 (20.9, 0.5)
Donepezil 5–10 mg 71 4.0 (0.13) 20.3 (20.7, 0.1) – – – – – –
Abbreviations: SE, standard error; CI, confidence interval; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; MMSE, Mini-Mental
Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CIBIC1, Clinician Interview-Based Impression of Change Plus Caregiver Input.
ADAS-Cog, CIBIC1, and CDR-SB: a negative difference represents benefit over placebo. *P , .01.
*From the week 24 analysis data set (includes all data from the primary analysis, up to and including the week 24 visit).
yFrom the week 48 analysis data set (includes all data from the analysis of the complete and final data set, up to and including the week 48 visit).
zIn Study 2, SB742457 and placebo were administered as an adjunct to stable donepezil therapy.
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both studies compared well with the protocol
assumptions. A recently reported phase 2 study
(LADDER) assessing the safety and efficacy of another
5-HT6 antagonist (idalopirdine, Lu AE58054) also
demonstrated an improvement in cognition compared
with placebo at 24 weeks in subjects maintained on done-
pezil [29]. The LADDER study did not demonstrate statis-
tically significant effects on secondary outcomes of
activities of daily living or global clinical measures where
the sample size was smaller than in Study 2 reported here.
A key difference between the studies that could poten-
tially account for the study outcomes is differences in subject
progression in the placebo arms compared with the active
treatment arms. In Study 2, clear progression was observed
on the clinical scales in the placebo group, whereas almost
no progression was observed in Study 1, or in the two previ-
ous studies of SB742457 as monotherapy [5,6]. This might
suggest that an adjunct population has a more predictable
and perhaps more rapid progression (in view of a more
established disease course). This might enable a clearer
outcome in clinical studies, compared with untreatedsubjects with a more recent diagnosis as in Study 1, where
the median time to diagnosis was approximately 1 year
less than in Study 2. Furthermore, subjects with the same
MMSE score in Study 1 and Study 2 may not be at the
same stage of disease as the subject’s true MMSE score in
Study 2 is inflated by the action of donepezil. Therefore,
although the mean MMSE scores were similar across the
two studies, this may hide the fact that subjects in Study 2
were at a more advanced stage of disease. Further adjunct
studies would be required to confirm these hypotheses.
The results reported here have important implications for
the design of future studies investigating symptomatic or
disease-modifying therapies in AD, and trials should ensure
that the subject population will progress during the course of
the study.
SB742457 was generally well tolerated as monotherapy
or when added to existing donepezil therapy. The incidence
of AEs was similar across treatment groups in each study and
overall, the most common AEs were nasopharyngitis, uri-
nary tract infection, headache, and diarrhea. The proportion
of subjects experiencing a SAE, or AE leading to withdrawal
was similar across treatment groups in Study 1 and slightly
Fig. 2. Results from analysis of change from baseline using a MMRM model in the assessment of treatment effect of SB742457 on the ADAS-Cog (A, B),
CIBIC1 (C), CDR-SB (D), ADCS-ADL (E, F), and RBANS (G, H) in the ITT population of Study 1 (panels A, C, E, G) and 2 (panels B, D, F, H). Data presented
as adjusted mean6 95% CI. Abbreviations: MMRM, mixed model for repeated measures; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Sub-
scale; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CI, confidence interval; CIBIC1, Clinician Interview-Based Impression of Change Plus Caregiver
Input; ADCS-ADL, Alzheimer’s Disease Co-operative Study-Activities of Daily Living Scale; RBANS, Repeatable Battery for Assessment of Neuropsycho-
logical Status; ITT, intent-to-treat.
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Table 4
On-treatment adverse events in 2% of subjects in any treatment arm (Study 1)
Preferred term
Number of subjects, n (%)
SB742457, 35 mg
(N 5 133)
SB742457, 15 mg
(N 5 145)
Donepezil, 5–10 mg
(N 5 151) Placebo (N 5 145) Total, N 5 574
Any AE 39 (29) 42 (29) 65 (43) 45 (31) 191 (33)
Headache 2 (2) 5 (3) 5 (3) 6 (4) 18 (3)
Nasopharyngitis 3 (2) 3 (2) 4 (3) 3 (2) 13 (2)
Dizziness 2 (2) 3 (2) 5 (3) 1 (,1) 11 (2)
Influenza 3 (2) 2 (1) 4 (3) 2 (1) 11 (2)
Diarrhea 2 (2) 0 3 (2) 5 (3) 10 (2)
Nausea 1 (,1) 2 (1) 5 (3) 2 (1) 10 (2)
Urinary tract infection 3 (2) 4 (3) 3 (2) 0 10 (2)
Insomnia 1 (,1) 2 (1) 5 (3) 0 8 (1)
Back pain 0 1 (,1) 3 (2) 3 (2) 7 (1)
Bronchitis 1 (,1) 3 (2) 1 (,1) 2 (1) 7 (1)
Hyperglycemia 2 (2) 3 (2) 1 (,1) 1 (,1) 7 (1)
Fall 2 (2) 0 1 (,1) 3 (2) 6 (1)
Hypertension 1 (,1) 1 (,1) 4 (3) 0 6 (1)
Agitation 2 (2) 1 (,1) 0 0 3 (,1)
Nightmare 0 0 3 (2) 0 3 (,1)
Hypercholesterolemia 2 (2) 0 0 0 2 (,1)
Abbreviation: AE, adverse event.
G. Maher-Edwards et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 23-36 33higher for subjects receiving SB742457 compared with pla-
cebo in Study 2. There did not appear to be any additional
AE findings of note with adjunctive SB742457 treatment
beyond those observed in previous monotherapy studies
[5,6]. There were four deaths in Study 1 (monotherapy);
one each in the placebo, SB742457 35 mg, and donepezil
treatment groups, and one in a nonrandomized subject. In
Study 2, the number of deaths was higher for SB742457
when added to donepezil compared with placebo.Table 5
On-treatment adverse events in 2% of subjects in any treatment arm (Study 2, w
Number of subjects, n (%)
SB742457 35 mg 1 donepezil
(N 5 236)
SB74
(N 5
Any AE 146 (62) 137 (6
Nasopharyngitis 18 (8) 19 (9
Urinary tract infection 13 (6) 11 (5
Diarrhea 11 (5) 12 (5
Fall 5 (2) 4 (2
Headache 7 (3) 8 (4
Hypertension 7 (3) 5 (2
Bronchitis 9 (4) 4 (2
Nausea 4 (2) 4 (2
Dizziness 3 (1) 5 (2
Cough 8 (3) 4 (2
Back pain 4 (2) 4 (2
Pneumonia 7 (3) 1 (,
Contusion 6 (3) 1 (,
Insomnia 6 (3) 2 (,
Edema peripheral 1 (,1) 6 (3
Upper respiratory tract infection 1 (,1) 4 (2
Vomiting 2 (,1) 5 (2
Abbreviation: AE, adverse event.Cerebrovascular accident/cerebral hemorrhage was the
only cause of death in more than one subject treated with
SB742457. Because of the small number of deaths in each
treatment group, it was not possible to determine a
temporal or dose relationship. None of the deaths in either
study were considered by the Investigator to be drug-
related. Mean changes in laboratory parameters, ECGs,
and vital signs were generally small and comparable in all
treatment groups in each study.eek 48 analysis)
2457 15 mg 1 donepezil
221)
Placebo 1 donepezil
(N 5 225) Total (N 5 682)
2) 125 (56) 408 (60)
) 17 (8) 54 (8)
) 16 (7) 40 (6)
) 9 (4) 32 (5)
) 13 (6) 22 (3)
) 6 (3) 21 (3)
) 7 (3) 19 (3)
) 3 (1) 16 (2)
) 8 (4) 16 (2)
) 7 (3) 15 (2)
) 2 (,1) 14 (2)
) 5 (2) 13 (2)
1) 4 (2) 12 (2)
1) 3 (1) 10 (1)
1) 2 (,1) 10 (1)
) 3 (1) 10 (1)
) 5 (2) 10 (1)
) 2 (,1) 9 (1)
G. Maher-Edwards et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 23-3634Pharmacokinetic analyses did not suggest any influence
of SB742457 on donepezil concentrations, or of donepezil
on SB742457 concentrations, with reported values in line
with expectations. There was also no peripheral pharmaco-
dynamic interaction in terms of effects on red blood cell
acetylcholinesterase activity. The effects observed with
SB742457 in Study 2 are therefore unlikely to be explained
by an interaction of SB742457 with the metabolism or direct
mechanism of action of donepezil.
In conclusion, neither study met the overall criteria for
success, but as an adjunct to donepezil, SB742457 was asso-
ciated with sustained improvements for up to 48 weeks in
cognition and ADL, compared with donepezil alone.Acknowledgments
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1. Systematic review: Study 1 sought to confirm find-
ings from earlier studies regarding the potential of
SB742457 as monotherapy in mild to moderate Alz-
heimer’s disease (AD). A donepezil arm was
included for assay sensitivity to enable bench-
marking to other historical studies.
Study 2 was the first adjunctive trial to investigate the
efficacy and safety of SB742457 when added to sta-
ble donepezil therapy in subjects with mild to moder-
ate AD.
2. Interpretation: Study 1 failed to detect any efficacy
for SB742457 as monotherapy and detected only
modest efficacy for donepezil, indicating minimal
assay sensitivity. Both SB742457 treatment arms
demonstrated less efficacy than in previous studies.
In Study 2, SB742457 35 mg, when added to stable
donepezil, improved cognition and functional status
compared with donepezil treatment alone and had
an acceptable safety profile.
The current results taken together with the earlier
SB742457457 monotherapy studies suggest that
SB742457 has limited utility as monotherapy but
may have utility as an adjunct therapy.
3. Future directions: Further research with SB742457
should seek to explore and confirm its potential as
an adjunct to existing symptomatic treatments.
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